Recent developments in polycystic kidney disease drug therapies, clinical trial results, and research breakthroughs for ADPKD patients.
Juntendo University's 12-month interim results presented at WCN 2026 show that ketogenic metabolic therapy achieved what no drug has done before — actual kidney volume decrease in ADPKD patients, with a striking dose-response correlation between ketone levels and kidney shrinkage.
Read full articleNovartis announced the presentation of its global Phase 3 trial design for farabursen (anti-miR-17) in ADPKD at the European Renal Association Congress 2026 in Glasgow, marking the next major step after extraordinary Phase 1b results that halted kidney growth.
Read full articleThe DoD-funded BEAT-PKD trial testing bempedoic acid in 120 ADPKD patients is approaching its estimated recruitment start date of July 2026, offering a kidney-specific AMPK activator as an alternative to metformin.
Read full articleChinese pharmaceutical company Jemincare has registered multiple Phase 1 studies for its PKD drug candidate JMKX003142, including a drug-drug interaction study estimated to begin in May 2026, signaling rapid clinical development.
Read full articleA Phase 2 trial of rotigotine — a dopamine agonist currently used for Parkinson's disease — has been registered for ADPKD (NCT06291116, 120 patients), exploring restoration of endothelial mechanosensitivity and NO release via dopamine D5 receptor activation.
Read full articleThe Cleveland Clinic has begun recruiting participants for an independent study evaluating the metabolic impacts of the Ren-Nu dietary program in PKD patients, providing crucial validation outside the original research group.
Read full articleAs of 2026, the most promising PKD drugs in development include farabursen (anti-miR-17 from Novartis, entering Phase 3), VX-407 (Vertex, Phase 2), ABBV-CLS-628 (Calico/AbbVie, Phase 2), AZD1613 (AstraZeneca, Phase 1), dapagliflozin (Phase 3 STOP-PKD trial), and bempedoic acid (Phase 2 BEAT-PKD trial). Farabursen showed the most impressive Phase 1b results, effectively halting kidney growth. See our full drug pipeline for all trials.
Clinical trial evidence from Juntendo University (2026) shows that ketogenic metabolic therapy achieved actual kidney volume decrease in ADPKD patients — the first time a dietary intervention has reversed kidney growth. The 12-month results showed a strong dose-response correlation between blood ketone levels and kidney shrinkage (Spearman rho = -0.86, p=0.012). A larger controlled trial with 50+ participants is underway, and the Cleveland Clinic has begun an independent validation study. Read our full keto & PKD guide for details.
Farabursen (formerly RGLS8429/CYX082) is an anti-miR-17 oligonucleotide developed by Novartis for ADPKD. It works by inhibiting microRNA-17, which restores production of polycystin-1 and polycystin-2 — the proteins whose deficiency causes the disease. In Phase 1b, farabursen halted kidney growth (0.05% vs 2.58% in placebo). Novartis acquired the drug for $1.7 billion and is launching a global Phase 3 trial in 2026. Read the full farabursen profile.
The fastest path to new PKD treatments includes repurposed drugs already FDA-approved for other conditions: dapagliflozin (SGLT2 inhibitor, Phase 3 results expected 2029) and bempedoic acid (AMPK activator, Phase 2 completing 2028). Farabursen, the most promising novel drug, could reach market by 2030–2031 if Phase 3 confirms Phase 1b results. Ketogenic dietary intervention is available now through programs like Ren-Nu. See our complete pipeline tracker for timelines.
Disclaimer: This information is for educational purposes only and is not medical advice. News articles are based on publicly available data from ClinicalTrials.gov, company press releases, and published research. Consult your nephrologist before making treatment decisions.
Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.
No spam. Unsubscribe anytime.